This News From Novo: A Warning for Eli Lilly Shareholders
A GLP-1 drug race is moving from injections to pills, reshaping the landscape for Novo Nordisk and Eli Lilly. Here’s ...
Knowing when to start retirement planning is crucial for a secure future. Gain insights that will help you prepare effectively for retirement.
15,993 articlesA GLP-1 drug race is moving from injections to pills, reshaping the landscape for Novo Nordisk and Eli Lilly. Here’s ...
As Stanford’s AI Index shows lagging adoption in the U.S., analysts say the real payoff comes from integration and tr...
What really moved Si-Bone in Q1 2026? Our practical analysis breaks down revenue trends, margins, and the company’s a...
Rising internal strife and political pressure push the FDA toward leadership change, with markets watching how the ag...
A practical, down-to-earth look at Howmet’s 2026 earnings outlook. This guide breaks down drivers, risks, and actiona...
In 2026, hiring stresses sharpen the focus on culture and teamwork. The steve jobs ‘beer test’ stands as a symbol of ...
Capricor is at a crossroads as 2026 earnings season unfolds. This article breaks down what to look for in capricor (c...
Westport's Q4 2025 earnings release offers clues about growth, margins, and cash flow. This article breaks down the t...
Nvidia CEO Jensen Huang describes a 1,000% surge in AI compute for agentic AI, triggering a broad rethink of data cen...
Tim Cook's travels to China are more than diplomacy. This piece outlines how what cook's trip china could mean for Ap...
Six ETFs now cover the entire grid-resilience thesis, from hardware and software to infrastructure and energy metals,...
A rapid AI-driven capex cycle is widening the performance split between cap-weighted and equal-weight NASDAQ funds, u...